| Quarter (USD) | Sep 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 80.54 mm | 80.54 mm | 80.54 mm | 80.54 mm | 80.54 mm | 80.54 mm |
| Cash burn (monthly) | 7.56 mm | 2.92 mm | 12.12 mm | 7.66 mm | (no burn) | 3.96 mm |
| Cash used (since last report) | 21.17 mm | 8.17 mm | 33.95 mm | 21.44 mm | n/a | 11.10 mm |
| Cash remaining | 59.37 mm | 72.37 mm | 46.59 mm | 59.10 mm | n/a | 69.44 mm |
| Runway (months of cash) | 7.9 | 24.8 | 3.8 | 7.7 | n/a | 17.5 |
| 13F holders | Current |
|---|---|
| Total holders | 39 |
| Opened positions | 18 |
| Closed positions | 33 |
| Increased positions | 7 |
| Reduced positions | 6 |
| 13F shares | Current |
|---|---|
| Total value | 96.07 bn |
| Total shares | 44.04 mm |
| Total puts | 17.70 k |
| Total calls | 1.70 k |
| Total put/call ratio | 10.4 |
| Largest owners | Shares | Value |
|---|---|---|
| Biotechnology Value Fund L P | 10.33 mm | $54.67 mm |
| BVF | 10.33 mm | $34.10 bn |
| Blue Owl Capital | 3.37 mm | $11.13 bn |
| Orbimed Advisors | 3.32 mm | $10.96 bn |
| ARK Investment Management | 2.63 mm | $8.68 bn |
| MPM Asset Management | 2.24 mm | $7.40 bn |
| MPM BioVentures 2014 | 2.24 mm | $76.41 mm |
| Versant Venture Capital V | 2.09 mm | $31.65 mm |
| Redmile | 1.94 mm | $6.41 bn |
| MPM Oncology Impact Management | 1.64 mm | $5.41 bn |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 17 Jun 24 | Molineaux Susan | Stock Option Common Shares | Grant | Acquire A | No | No | 3.8 | 27,200 | 103.36 k | 27,200 |
| 17 Jun 24 | Schafer Carol | Stock Option Common Shares | Grant | Acquire A | No | No | 3.8 | 27,200 | 103.36 k | 27,200 |
| 17 Jun 24 | Morrison Briggs | Stock Option Common Shares | Grant | Acquire A | No | No | 3.8 | 27,200 | 103.36 k | 27,200 |
| 17 Jun 24 | Civik Thomas | Stock Option Common Shares | Grant | Acquire A | No | No | 3.8 | 27,200 | 103.36 k | 27,200 |
| 17 Jun 24 | Stein Steven H | Stock Option Common Shares | Grant | Acquire A | No | No | 3.8 | 54,000 | 205.20 k | 54,000 |
